RSV Vaccine Market To Reach 731 million by 2040, Due To Increasing Awareness on Preventive Therapies for RSV Infections| Roots Analysis

According to our latest market report "RSV Vaccine Market, Till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players", the RSV Vaccine market size is projected to reach USD 731 million by 2040 from USD 1,149 million in current year, during the forecast period.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-quote.html

In the dynamic landscape of preventive therapies for respiratory syncytial virus infections, RSV vaccines have remarkably revolutionized the approach of managing RSV diseases. These vaccines are selectively designed and developed to stimulate the immune system to produce a protective response against the virus, thus reducing the risk of severe illness. Further, the incorporation of advanced technologies such as mRNA, nanoparticle and vector-based platforms to develop RSV vaccines have assisted healthcare professionals to provide safe and effective disease management. These innovative RSV vaccines have significantly improved patient care as well as healthcare outcomes. Considering such promising outcomes, RSV vaccine developers are actively involved in developing more advanced vaccines, that have the ability to reduce the chances of complications associated with the severe RSV infections.

RSV Vaccine Market Segments

Based on the type of vaccine, the market is segmented into Subunit / Viral-like-Particle (VLP) Vaccines, Live Attenuated Vaccines and mRNA Vaccines.

1. The subunit / viral-like-particle (VLP) vaccines segment is likely to lead the market for RSV vaccines, capturing the largest revenue share of 98% in the current year.
2. The live attenuated vaccine segment is anticipated to show the highest growth rate of 0.2% during the forecast period.

Based on the route of administration, the market is segmented into Intramuscular and Other Routes.

1. The RSV vaccines administered through intramuscular route led the RSV vaccine market, capturing the entire revenue share of 100% in the current year.
2. The other routes of administration such as intranasal, intradermal and oral routes are anticipated to enter the domain, during the forecast period.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-sample.html

Based on the target patient population, the market is segmented into Elderly Individuals, Infants / Children and Pregnant Individuals.

1. The RSV vaccines for elderly individuals led the RSV vaccine market, capturing the largest revenue share of close to 95% in the current year.
2. The RSV vaccines for infants / children are anticipated to emerge during the forecast period.

Based on the distribution channel, the market is segmented into Pharmacies and Drug Stores, Government / Institutional Suppliers and Others.

1. The Pharmacies and Drug Stores led the RSV vaccine market, capturing the largest revenue share of 80% in the current year.
2. The Others segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 3.9% during the forecast period.

Based on the Regional Insights, the market is segmented into North America and Europe.

1. North America dominated the RSV vaccine market and accounted for the largest revenue share of around 85% in the current year.
2. In Europe, the RSV vaccine market is anticipated to capture 15% of the overall market share, till 2040.

RSV Vaccine Market Regional Outlook
Based on the key geographical regions, the RSV Vaccine market can be segmented into two major regions, including North America and Europe. Led by the US, North America is anticipated to capture the majority share of the RSV vaccine market in the current year and this trend is likely to remain unchanged during the forecast period. Further, the RSV vaccines in North America is accounted to be the fastest-growing segment of the market. The growth of the RSV vaccine market in the region is driven by increased prevalence of RSV infections resulting in a rise in the interest of various pharmaceutical companies towards the development of innovative and advanced vaccines.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/rsv-vaccine-market.html

Key Report Takeaways
1. The rising demand for RSV vaccines has led to a notable increase in vaccine pipeline, with around 65 vaccines currently under preclinical and clinical stages of development
2. Over 40% of the RSV vaccine developers are small players; demonstrating a considerable number of new entrants within the market owing to the increased awareness of RSV infections
3. Since 2020, more than 330 patents have been filed / granted focused on the research and development of RSV vaccines across the globe; further, majority of the patents were filed in North America (>50%)
4. The growing prevalence of respiratory syncytial virus infections, coupled with the increasing pace of technological advancements is driving the RSV vaccine market and positioning it for steady growth in the foreseeable future
5. The RSV vaccine market is anticipated to reach 731 million by 2040; subunit / viral-like-particle (VLP) vaccine segment is expected to capture the majority share (over 95%) of the market

RSV Vaccine Market Key Players
1. Examples of key companies engaged in RSV vaccine market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Beijing Advaccine Biotechnology, GlaxoSmithKline, Icosavax (A company of AstraZeneca), Moderna, Pfizer and Sanofi.

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.